open access

Vol 64, No 12 (2006)
Other
Published online: 2006-12-21
Submitted: 2012-12-28
Get Citation

Original article
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Anna Kozieradzka, Karol Kamiński, Witold Pepiński, Jerzy Janica, Janusz Korecki, Konrad Skolimowski, Emilia Frankowska, Paweł Kralisz, Tomasz A. Bonda, Sławomir Dobrzycki, Włodzimierz Jerzy Musiał
Kardiol Pol 2006;64(12):1350-1355.

open access

Vol 64, No 12 (2006)
Other
Published online: 2006-12-21
Submitted: 2012-12-28

Abstract

Introduction: Glycoprotein IIb/IIIa (GP IIb/IIIa) is a platelet receptor composed of two subunits coded by individual genes. GP IIIa gene has two alleles: A1 and A2. The A2 allele determines higher platelet activity and was investigated many times as a potential risk factor of ACS. The influence of A1/A2 polymorphism on the prognosis in patients with ST-segment elevation myocardial infarction (STEMI) has not been analysed so far. Aim: Evaluation of the relationship between GP IIb/IIIa A1/A2 gene polymorphism and one-year prognosis in patients with STEMI treated with primary percutaneous coronary intervention (pPCI). Methods: 171 patients (23.9% – women, 39.7% – anterior MI) with STEMI treated successfully with pPCI as well as 121 healthy subjects from a reference group were enrolled in the study. Genotyping was performed using restriction fragment length polymorphism analysis (RFLP). In one-year follow-up the primary end point included deaths and infarctions. The following methods were used in statistical analysis: c2 as well as Mann-Whitney test, Kaplan-Meier survival analysis, Cox regression model and multivariate analysis. Results: The percentage of A2 allele carriers was similar in STEMI patients and in subjects from the reference group (27.4% vs. 21.5%, p=0.24). No statistically significant difference in the incidence of primary end point between the A1A1 homozygotes and A2 allele carriers (A1A2/A2A2 genotype) was observed among STEMI patients. In Cox regression analysis, the variables associated with death or MI were: ejection fraction (RR 0.912, p=0.01) and systolic blood pressure on admission (RR 0.97, p=0.049). The variables categorised as unfavourable predictors included: Killip class >2 and heart ratio on admission >100/min (p

Abstract

Introduction: Glycoprotein IIb/IIIa (GP IIb/IIIa) is a platelet receptor composed of two subunits coded by individual genes. GP IIIa gene has two alleles: A1 and A2. The A2 allele determines higher platelet activity and was investigated many times as a potential risk factor of ACS. The influence of A1/A2 polymorphism on the prognosis in patients with ST-segment elevation myocardial infarction (STEMI) has not been analysed so far. Aim: Evaluation of the relationship between GP IIb/IIIa A1/A2 gene polymorphism and one-year prognosis in patients with STEMI treated with primary percutaneous coronary intervention (pPCI). Methods: 171 patients (23.9% – women, 39.7% – anterior MI) with STEMI treated successfully with pPCI as well as 121 healthy subjects from a reference group were enrolled in the study. Genotyping was performed using restriction fragment length polymorphism analysis (RFLP). In one-year follow-up the primary end point included deaths and infarctions. The following methods were used in statistical analysis: c2 as well as Mann-Whitney test, Kaplan-Meier survival analysis, Cox regression model and multivariate analysis. Results: The percentage of A2 allele carriers was similar in STEMI patients and in subjects from the reference group (27.4% vs. 21.5%, p=0.24). No statistically significant difference in the incidence of primary end point between the A1A1 homozygotes and A2 allele carriers (A1A2/A2A2 genotype) was observed among STEMI patients. In Cox regression analysis, the variables associated with death or MI were: ejection fraction (RR 0.912, p=0.01) and systolic blood pressure on admission (RR 0.97, p=0.049). The variables categorised as unfavourable predictors included: Killip class >2 and heart ratio on admission >100/min (p
Get Citation

Keywords

glycoprotein IIb/IIIa (GP IIb/IIIa); polymorphism; RFLP; STEMI; pPCI

About this article
Title

Original article
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 64, No 12 (2006)

Pages

1350-1355

Published online

2006-12-21

Bibliographic record

Kardiol Pol 2006;64(12):1350-1355.

Keywords

glycoprotein IIb/IIIa (GP IIb/IIIa)
polymorphism
RFLP
STEMI
pPCI

Authors

Anna Kozieradzka
Karol Kamiński
Witold Pepiński
Jerzy Janica
Janusz Korecki
Konrad Skolimowski
Emilia Frankowska
Paweł Kralisz
Tomasz A. Bonda
Sławomir Dobrzycki
Włodzimierz Jerzy Musiał

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl